References
- Matutes E. T-cell prolymphocytic leukemia. Cancer Control 1998; 5: 19–24
- Matutes E., Brito-Babapulle V., Swansbury J., Ellis J., Morula R., Dearden C., Sempere A., Catovsky D. Clinical and laboratory features of 78 cases of T-prolymphocytic leukaemia. Blood 1991; 78: 3269–3274
- Jaffe E., Harris N., Diebold J., Muller-Hermelink H.-K. World Health Organization. Classification of neoplastic diseases of hematopoietic and lymphoid tissues. American Journal of Clinical Pathology 1999; 111((Suppl. 1))S8-S12
- Mercieca J., Matutes E., Dearden C., Maclennan K., Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. Journal of Clinical Oncology 1994; 12: 2588–2593
- Pawson R., Dyer M. J., Barge R., Matutes E., Thornton P., Emmett E., Kluin-Nelemans J. C., Fibbe W. E., Willenza R., Catovsky D. 'Treatment of T-prolymphocytic leukaemia with human CD52 antibody. Journal of Clinical Oncology 1997; 15: 2667–2672
- Dearden C., Matutes E., Dyer M. J., Catovsky D. CAMPATH-1H treatment of T-PLL. Blood 1999; 94((Suppl. 1))660a
- Gilleece M. H., Dexter T. M. Effects of CAMPATH-1H antibody on human haemopoietic progenitors in vitro. Blood 1993; 82: 807–812
- Ginaldi L., De Martinis M., Matutes E., Farahat N., Morilla R., Dyer M. J., Catovsky D. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to CAMPATH-1H. Leukemia Research 1998; 22: 185–191
- Mori N., Ogawa R., Wake A., Nagata K., Sato T., Tsukada J., Nakata K., Misago M., Morimoto I., Oda S. Adult T-cell leukemia with cervical bone tumor showing immunophenotypic change. Rinsho Ketsueki 1992; 33: 75–81
- Kubota K., Tanaka H., Suda K., Tsuboyama A., Sakamoto S., Nakahara N., Kawai T., Takashishi A., Mori S., Miura Y. Morphological and immunological change in the predominant type of leukaemic cells in a patient with T-cell chronic lymphocytic leukaemia. Scandinavian Journal of Haematology 1986; 36: 439–443